<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9836">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01795105</url>
  </required_header>
  <id_info>
    <org_study_id>031-KOA-1101n</org_study_id>
    <nct_id>NCT01795105</nct_id>
  </id_info>
  <brief_title>ABF Tourette's Disorder PMS</brief_title>
  <official_title>Post-Marketing Surveillance of Safety and Efficacy of Abilify® Tablets in Korean Patients With Tourette's Disorder Under the &quot;New Drug Re-Examination&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co.,Ltd.</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Post-Marketing Surveillance study of Abilify® tablets in accordance with Korean
      regulations on New Drug Re-examination (i.e. New Drug Re-examination Standards: KFDA
      Notification No. 2010-94 dated 27 December 2010).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted in a prospective, single-arm, multi-center format. As this
      study is observational in nature, the patient's follow-up is not prescriptive in nature and
      must be left up to the judgment of the physician (investigator), within the period of
      observation set forth in the protocol.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Frequency (n) and Percentage(%) of subjects with Adverse event</measure>
    <time_frame>Follow-up at least once from baseline to 6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in the TS-CGI</measure>
    <time_frame>at least 6, 12 weeks interval  from baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean change in the TS-CGI from baseline to next visit(at least 6, 12 weeks interval  from baseline) post-treatment</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Tourette's Disorder</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric patients 6 to 18 years of age with Tourette's Disorder according to the approved
        product market authorization
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pediatric patients 6 to 18 years of age with Tourette's Disorder

          -  Patients who are prescribed Abilify® treatment as per investigator's medical
             judgment.

          -  Patients who gave written authorization to use their personal and health data

          -  Patients starting Abilify® treatment after agreement is in place

        Exclusion Criteria:

          -  Patients with known hypersensitivity to Aripiprazole  or any excipients of Abilify®

          -  Patients who have been treated with Abilify®

          -  Patients with rare hereditary problems of galactose intolerance, the lapp lactase
             deficiency, or glucose-galactose malabsorption

          -  Patients with score 0(Not assessed) or 1(Normal, not at all ill) in the TS-CGI-S

          -  Patients participating in other clinical trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeong-Seop Lee, Ph.D</last_name>
      <email>soulfree@inha.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Jeong-Seop Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae Won Park, Ph.D</last_name>
      <email>ptaewon@jbnu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Tae Won Park</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soo Churl Cho, Ph.D</last_name>
      <email>soochurl@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Soo Churl Cho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 17, 2013</lastchanged_date>
  <firstreceived_date>January 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tourette Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
